Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions

Catheterization and Cardiovascular Interventions

Volumn 85, Issue 2, 2015, Pages 207-215

  Teirstein, Paul S ^a   Meredith, Ian T ^b   Feldman, Robert L ^c   Rabinowitz, A Charles ^d   Cannon, Louis A ^e   Lee, Tommy C ^f   Dens, Joseph ^g   Dubois, Christophe L ^h,i   Mooney, Michael R ^j   Pompili, Vincent J ^k   Saito, Shigeru ^l   Allocco, Dominic J ^m   Dawkins, Keith D ^m   Stone, Gregg W ⁿ  

^a SCRIPPS CLINIC   (United States)

^b MONASH MEDICAL CENTRE   (Australia)

^c Munroe Regional Med Center   (United States)

^d Department of Emergency Medicine   (United States)

^e Mc Laren Northern Michigan   (United States)

^f Bakersfield Memorial Hospital   (United States)

^g DEPARTMENT OF CARDIOLOGY   (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^l SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^m BOSTON SCIENTIFIC CORPORATION   (United States)

ⁿ Department of Medicine   (United States)

more..

Author keywords

Coronary stenosis; Drug eluting; Everolimus; Randomized controlled trial; Stents

Indexed keywords

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MALE; PATIENT SAFETY; PLATINUM CHROMIUM EVEROLIMUS ELUTING STENT; RISK BENEFIT ANALYSIS; STENT THROMBOSIS; TREATMENT FAILURE; VEIN DIAMETER; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DEVICES; DRUG ELUTING STENT; EUROPE; JAPAN; MIDDLE AGED; MULTICENTER STUDY; NEW ZEALAND; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; PROSTHESIS; TIME; TREATMENT OUTCOME; UNITED STATES;

CARDIOVASCULAR AGENT; CHROMIUM; EVEROLIMUS; PLATINUM; RAPAMYCIN;

AGED; CARDIOVASCULAR AGENTS; CHROMIUM; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EUROPE; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEW ZEALAND; PERCUTANEOUS CORONARY INTERVENTION; PLATINUM; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84922062184     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25565     Document Type: Article

References (30)

1. Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S, Di Francesco L, Finci L, Di Mario C, Colombo A. Angiographic and clinical outcome following coronary stenting of small vessels: A comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998;32:1610-1618.
2. Kereiakes DJ. Coronary small-vessel stenting in the era of drug elution. Rev Cardiovasc Med 2004;5(Suppl 2):S34-S45.
3. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006;113:2293-2300.
4. Marzocchi A, Saia F, Piovaccari G, et al. Long-term safety and efficacy of drug-eluting stents: Two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 2007;115:3181-3188.
5. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005;294:1215-1223.
6. Turco MA, Kansal AR, Stern S, Amorosi SL, Underwood PL, Lissovoy GD, Dawkins KD. Economic modeling of new stent platforms to evaluate cost effectiveness: Analysis of the TAXUS Liberte versus TAXUS Express stents. J Interv Cardiol 2012;25:353-363.
7. Turco M, Ormiston JA, Popma JJ, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: One-year results from the TAXUS ATLAS program. J Am Coll Cardiol Interv 2008;1:699-709.
8. Bartorelli AL, Serruys PW, Miquel-Hebert K, Yu S, Pierson W, Stone GW. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials. Catheter Cardiovasc Interv 2010;76:60-66.
9. Cannon L, Kereiakes DJ, Mann T, et al. A prospective evaluation of the safety and efficacy of TAXUS Element paclitax-eleluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: The PERSEUS Small Vessel Trial. EuroIntervention 2011;6:920-927.
10. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: A meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011;58:1569-1577.
11. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: A mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-2891.
12. Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimus-eluting stents: Meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012;5:357-364.
13. Menown IB, Noad R, Garcia EJ, Meredith I. The platinum chromium element stent platform: From alloy, to design, to clinical practice. Adv Ther 2010;27:129-141.
14. O'Brien BJ, Stinson JS, Larsen SR, Eppihimer MJ, Carroll WM. A platinum-chromium steel for cardiovascular stents. Biomaterials 2010;31:3755-3761.
15. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010;375:201-209.
16. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention 2006;2:286-294.
17. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008;299:1903-1913.
18. De la Torre Hernandez J, Garcia Camarero T, Lerena P, Lee DH, Sainz Laso F, Frances Santamaria V, Fernandez Menendez M, Martin Gorria G, Zueco J. An all comers randomized trial comparing Xience Prime and Promus Element stents: Preliminary results (Abstract). J Am Coll Cardiol 2011;58(20, Suppl):B68.
19. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS Element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol 2011;57:1700-1708.
20. Meredith I, Teirstein PS, Stone G, et al. The PLATINUM small vessel trial: Evaluation of the novel thin-strut platinum-chromium PROMUS Element small vessel everolimus-eluting stent (abstr). EuroIntervention 2011;7(Suppl M):M157.
21. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-2384.
22. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351.
23. Sarno G, Lagerqvist B, Carlsson J, Olivecrona G, Nilsson J, Calais F, Gotberg M, Nilsson T, Sjogren I, James S. Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Int J Cardiol 2013;167:148-150.
24. Mutoh M, Ishikawa T, Hasuda T, et al. Predictors of target lesion revascularization and documented stent thrombosis beyond 30 days after sirolimus-eluting stent implantation: Retrospective analysis in consecutive 1,070 angiographic follow-up lesions. Circ J 2007;71:1328-1331.
25. Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: Five-year outcome of the j-Cypher Registry. Circulation 2012;125:584-591.
26. Wykrzykowska JJ, Serruys PW, Onuma Y, et al. Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy. J Am Coll Cardiol Interv 2009;2:861-870.
27. Wykrzykowska JJ, Raber L, de Vries T, et al. Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: Results from the LEADERS multicentre trial substudy. EuroIntervention 2009;5:310-317.
28. Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006;114:2148-2153.
29. Mamas MA, Williams PD. Longitudinal stent deformation: Insights on mechanisms, treatments and outcomes from the Food and Drug Administration Manufacturer and User Facility Device Experience database. EuroIntervention 2012;8:196-204.
30. Kereiakes DJ, Popma J, Cannon L, et al. Longitudinal stent deformation: Quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. EuroIntervention 2012;8:187-195.